Correction: Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial (The Lancet Diabetes & Endocrinology (2018) 6(2) (114–121), (S221385871730400X) (10.1016/S2213-8587(17)30400-X));Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial

The Lancet Diabetes and Endocrinology

Volumn 6, Issue 2, 2018, Pages 114-121

  Ballmann, Manfred ^a,b   Hubert, Dominique ^c,d   Assael, Baroukh M ^e,f   Staab, Doris ^g   Hebestreit, Alexandra ^h   Naehrlich, Lutz ⁱ   Nickolay, Tanja ^j   Prinz, Nicole ^k,l   Holl, Reinhard W ^k,l   Staden, Ute ^m   Claßen, Martin ^m   Schuster, Antje ^m   Mellies, Uwe ^m   Posselt, Hans Georg ^m   Wiebel, Matthias ^m   Rietschel, Ernst ^m   Stern, Martin ^m   Teschler, Helmut ^m   Smaczny, Christina ^m   Köhnlein, Thomas ^m   Wienhausen Wilke, Vera ^m   Claaß, Andreas ^m   Biedermann, Thomas ^m   Dockter, Gerd ^m   Köster, Holger ^m   Hebestreit, Helge ^m   Ballke, Ernst Hinrich ^m   Heuer, Hans Eberhard ^m   Kamin, Wolfgang ^m   Küster, Peter ^m   Szczepanski, Rüdiger ^m   Keller, Klaus Michael ^m   Generlich, Horst ^m   Bresser, Hans Georg ^m   Kopp, Matthias ^m   Herting, Egbert ^m   Feickert, Hans Joachim ^m   Hautz, Jürgen ^m   Schilling, Birgit ^m   Meyer, Egbert ^m   Mall, Marcus A ^m   Wiebicke, Wolfram ^m   Tegtmeyer, Friedrich Karl ^m   Honer, Marguerite ^m   Mosnier Pudar, Helen ^m   Lenoir, Gérard ^m   Robert, Jean Jacques ^m   Kessler, Laurence ^m   Weiss, Laurence ^m   Nove Josserand, Raphaële ^m   Vantyghem, Marie Christine ^m   Munck, Anne ^m   Wizla, Nathalie ^m   Leroy, Sylvie ^m   Loeuille, Guy André ^m   Serreau, Raphaël ^m   Aissat, Fawzia ^m   Thalhammer, Gabriela H ^m   Huttegger, Isidor ^m   Eichler, Irmgard ^m   Götz, Manfred ^m   more..

^a ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c Institut Cochin   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e UNIVERSITY HOSPITAL OF VERONA   (Italy)

^f UNIVERSITY OF MILAN   (Italy)

^g HUMBOLDT UNIVERSITY   (Germany)

^h UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

ⁱ JUSTUS LIEBIG UNIVERSITY   (Germany)

^j UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^k UNIVERSITY OF ULM   (Germany)

^l GERMAN CENTER FOR DIABETES RESEARCH DZD   (Germany)

^m NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; MONOCOMPONENT INSULIN; NEUTRAL INSULIN; REPAGLINIDE; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; CARBAMIC ACID DERIVATIVE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; INSULIN; PIPERIDINE DERIVATIVE;

ADOLESCENT; ADULT; ARTICLE; AUSTRIA; CARDIOVASCULAR DISEASE; CHILD; CONTROLLED STUDY; CYSTIC FIBROSIS; DIABETES MELLITUS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FRANCE; GASTROINTESTINAL SYMPTOM; GERMANY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HOSPITAL ADMISSION; HUMAN; HYPERGLYCEMIA; HYPERTRANSAMINASEMIA; HYPOGLYCEMIA; INTENTION TO TREAT ANALYSIS; ITALY; KIDNEY DISEASE; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; VIRUS INFECTION; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; FOLLOW UP; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOLOGY; PATHOPHYSIOLOGY; PROGNOSIS; YOUNG ADULT;

ADOLESCENT; ADULT; BIOMARKERS; BLOOD GLUCOSE; CARBAMATES; CHILD; CYSTIC FIBROSIS; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; GLYCATED HEMOGLOBIN A; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; PIPERIDINES; PROGNOSIS; YOUNG ADULT;

EID: 85035345718     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(19)30092-0     Document Type: Erratum

References (31)

1. Ode, KL, Moran, A, New insights into cystic fibrosis-related diabetes in children. Lancet Diabetes Endocrinol 1 (2013), 52–58.
2. Rana, M, Munns, CF, Selvadurai, HC, et al. Increased detection of cystic-fibrosis-related diabetes in Australia. Arch Dis Child 96 (2011), 823–826.
3. Knudsen, KB, Mathiesen, ER, Eriksen, V, et al. The development of diabetes among Danish cystic fibrosis patients over the last two decades. Pediatr Diabetes 16 (2015), 219–226.
4. American Diabetes Association. (2) Classification and diagnosis of diabetes. Diabetes Care 38:suppl (2015), S8–S16.
5. Konrad, K, Thon, A, Fritsch, M, et al. Comparison of cystic fibrosis-related diabetes with type 1 diabetes based on a German/Austrian pediatric diabetes registry. Diabetes Care 36 (2013), 879–886.
6. Mohan, K, Miller, H, Dyce, P, et al. Mechanisms of glucose intolerance in cystic fibrosis. Diabet Med 26 (2009), 582–588.
7. Kelly, A, Moran, A, Update on cystic fibrosis-related diabetes. J Cyst Fibros 12 (2013), 318–331.
8. Scheuing, N, Berger, G, Bergis, D, et al. Adherence to clinical care guidelines for cystic fibrosis-related diabetes in 659 German/Austrian patients. J Cyst Fibros 13 (2014), 730–736.
9. Moran, A, Brunzell, C, Cohen, RC, et al. Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care 33 (2010), 2697–2708.
10. Milla, CE, Warwick, WJ, Moran, A, Trends in pulmonary function in patients with cystic fibrosis correlate with the degree of glucose intolerance at baseline. Am J Respir Crit Care Med 162 (2000), 891–895.
11. Adler, AI, Shine, B, Haworth, C, Leelarathna, L, Bilton, D, Hyperglycemia and death in cystic fibrosis-related diabetes. Diabetes Care 34 (2011), 1577–1578.
12. Middleton, PG, Wagenaar, M, Matson, AG, et al. Australian standards of care for cystic fibrosis-related diabetes. Respirology 19 (2014), 185–192.
13. The UK Cystic Fibrosis Trust Diabetes Working Group. Cystic fibrosis: our focus. Management of cystic fibrosis related diabetes mellitus—report of the UK Cystic Fibrosis Trust Diabetes Working Group. https://www.cysticfibrosis.org.uk/∼/media/documents/the-work-we-do/care/consensus-docs-with-new-address/cfrd-mellitus.ashx?la=en, 2004 (accessed Sept 19, 2017).
14. Onady, GM, Stolfi, A, Insulin and oral agents for managing cystic fibrosis-related diabetes. Cochrane Database Syst Rev, 4, 2016 CD004730.
15. Rosenecker, J, Eichler, I, Barmeier, H, von der Hardt, H, Diabetes mellitus and cystic fibrosis: Comparison of clinical parameters in patients treated with insulin versus oral glucose-lowering agents. Pediatr Pulmonol 32 (2001), 351–355.
16. Sawicki, GS, Sellers, DE, Robinson, WM, High treatment burden in adults with cystic fibrosis: challenges to disease self-management. J Cyst Fibros 8 (2009), 91–96.
17. Ziaian, T, Sawyer, MG, Reynolds, KE, et al. Treatment burden and health-related quality of life of children with diabetes, cystic fibrosis and asthma. J Paediatr Child Health 42 (2006), 596–600.
18. Cai, Z, Lansdell, KA, Sheppard, DN, Inhibition of heterologously expressed cystic fibrosis transmembrane conductance regulator Cl-channels by non-sulphonylurea hypoglycaemic agents. Br J Pharmacol 128 (1999), 108–118.
19. Moran, A, Phillips, J, Milla, C, Insulin and glucose excursion following premeal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care 24 (2001), 1706–1710.
20. O'Riordan, SM, Robinson, PD, Donaghue, KC, Moran, A, Management of cystic fibrosis-related diabetes in children and adolescents. Pediatr Diabetes 10:suppl 12 (2009), 43–50.
21. Ballmann, M, Hubert, D, Assael, BM, Kronfeld, K, Honer, M, Holl, RW, Open randomised prospective comparative multi-centre intervention study of patients with cystic fibrosis and early diagnosed diabetes mellitus. BMC Pediatr, 14, 2014, 70.
22. Mueller-Brandes, C, Holl, RW, Nastoll, M, Ballmann, M, New criteria for impaired fasting glucose and screening for diabetes in cystic fibrosis. Eur Respir J 25 (2005), 715–717.
23. Scheuing, N, Holl, RW, Dockter, G, et al. Diabetes in cystic fibrosis: multicenter screening results based on current guidelines. PLoS One, 8, 2013, e81545.
24. Alberti, KG, Zimmet, PZ, Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15 (1998), 539–553.
25. Scheuing, N, Holl, RW, Dockter, G, et al. High variability in oral glucose tolerance among 1,128 patients with cystic fibrosis: a multicenter screening study. PLoS One, 9, 2014, e112578.
26. Hankinson, JL, Odencrantz, JR, Fedan, KB, Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 159 (1999), 179–187.
27. 1c variability and risk of microvascular complications in adolescents with type 1 diabetes. J Clin Endocrinol Metab 101 (2016), 3257–3263.
28. Roberts, R, Speight, L, Lee, J, et al. Retinal screening of patients with cystic fibrosis-related diabetes in Wales—a real eye opener. J Cyst Fibros 14 (2015), 282–284.
29. Moran, A, Pekow, P, Grover, P, et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care 32 (2009), 1783–1788.
30. Onady, GM, Langdon, LJ, Insulin versus oral agents in the management of cystic fibrosis related diabetes: a case based study. BMC Endocr Disord, 6, 2006, 4.
31. Mohan, K, Miller, H, Burhan, H, Ledson, MJ, Walshaw, MJ, Management of cystic fibrosis related diabetes: a survey of UK cystic fibrosis centers. Pediatr Pulmonol 43 (2008), 642–647.